Cargando…

Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)

Diabetic neuropathy (DN) is a frequent complication of diabetes mellitus (DM) with severe consequences as it progresses and influences all human body systems. This review discusses the risk factors for DN, the main characteristics of the clinical forms of DN, the screening methods and the current th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bondar, Andrei, Popa, Amorin Remus, Papanas, Nikolaos, Popoviciu, Mihaela, Vesa, Cosmin Mihai, Sabau, Monica, Daina, Cristian, Stoica, Roxana Adriana, Katsiki, Niki, Stoian, Anca Pantea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111877/
https://www.ncbi.nlm.nih.gov/pubmed/33986855
http://dx.doi.org/10.3892/etm.2021.10122
_version_ 1783690581096005632
author Bondar, Andrei
Popa, Amorin Remus
Papanas, Nikolaos
Popoviciu, Mihaela
Vesa, Cosmin Mihai
Sabau, Monica
Daina, Cristian
Stoica, Roxana Adriana
Katsiki, Niki
Stoian, Anca Pantea
author_facet Bondar, Andrei
Popa, Amorin Remus
Papanas, Nikolaos
Popoviciu, Mihaela
Vesa, Cosmin Mihai
Sabau, Monica
Daina, Cristian
Stoica, Roxana Adriana
Katsiki, Niki
Stoian, Anca Pantea
author_sort Bondar, Andrei
collection PubMed
description Diabetic neuropathy (DN) is a frequent complication of diabetes mellitus (DM) with severe consequences as it progresses and influences all human body systems. This review discusses the risk factors for DN, the main characteristics of the clinical forms of DN, the screening methods and the current therapeutic options. Distal symmetric DN is the primary clinical form, and DM patients should be screened for this complication. The most important treatment of DN remains good glucose control, generally defined as HbA1c ≤7%. Symptomatic treatment improves life quality in diabetic patients. Pharmacological agents such as alpha (α)-lipoic acid and benfotiamine have been validated in several studies since they act on specific pathways such as increased oxidative stress (α-lipoic acid exerts antioxidant effects) and the excessive production of advanced glycosylation products (benfotiamine may inhibit their production via the normalization of glucose). Timely diagnosis of DN is significant to avoid several complications, including lower limb amputations and cardiac arrhythmias.
format Online
Article
Text
id pubmed-8111877
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-81118772021-05-12 Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review) Bondar, Andrei Popa, Amorin Remus Papanas, Nikolaos Popoviciu, Mihaela Vesa, Cosmin Mihai Sabau, Monica Daina, Cristian Stoica, Roxana Adriana Katsiki, Niki Stoian, Anca Pantea Exp Ther Med Review Diabetic neuropathy (DN) is a frequent complication of diabetes mellitus (DM) with severe consequences as it progresses and influences all human body systems. This review discusses the risk factors for DN, the main characteristics of the clinical forms of DN, the screening methods and the current therapeutic options. Distal symmetric DN is the primary clinical form, and DM patients should be screened for this complication. The most important treatment of DN remains good glucose control, generally defined as HbA1c ≤7%. Symptomatic treatment improves life quality in diabetic patients. Pharmacological agents such as alpha (α)-lipoic acid and benfotiamine have been validated in several studies since they act on specific pathways such as increased oxidative stress (α-lipoic acid exerts antioxidant effects) and the excessive production of advanced glycosylation products (benfotiamine may inhibit their production via the normalization of glucose). Timely diagnosis of DN is significant to avoid several complications, including lower limb amputations and cardiac arrhythmias. D.A. Spandidos 2021-07 2021-04-29 /pmc/articles/PMC8111877/ /pubmed/33986855 http://dx.doi.org/10.3892/etm.2021.10122 Text en Copyright: © Bondar et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Bondar, Andrei
Popa, Amorin Remus
Papanas, Nikolaos
Popoviciu, Mihaela
Vesa, Cosmin Mihai
Sabau, Monica
Daina, Cristian
Stoica, Roxana Adriana
Katsiki, Niki
Stoian, Anca Pantea
Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)
title Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)
title_full Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)
title_fullStr Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)
title_full_unstemmed Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)
title_short Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)
title_sort diabetic neuropathy: a narrative review of risk factors, classification, screening and current pathogenic treatment options (review)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111877/
https://www.ncbi.nlm.nih.gov/pubmed/33986855
http://dx.doi.org/10.3892/etm.2021.10122
work_keys_str_mv AT bondarandrei diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview
AT popaamorinremus diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview
AT papanasnikolaos diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview
AT popoviciumihaela diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview
AT vesacosminmihai diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview
AT sabaumonica diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview
AT dainacristian diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview
AT stoicaroxanaadriana diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview
AT katsikiniki diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview
AT stoianancapantea diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview